ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Gene therapy for pompe disease effective in mice, poised for human trials – EurekAlert (press release)

EurekAlert (press release)Gene therapy for pompe disease effective in mice, poised for human trialsEurekAlert (press release)The Duke-led research team found that a single small dose of gene therapy was as effective as enzyme replacement therapy (ERT) … Continue reading

2017-01-26 Michael Zand NEWS

Cellecta Awarded Phase II SBIR Grant to Finalize Development of CRISPR Screening Platform – GenomeWeb

Continue reading

2017-01-26 Michael Zand NEWS

Mature heart muscle cells created in the laboratory from stem cells – Science Daily

EurekAlert (press release)Mature heart muscle cells created in the laboratory from stem cellsScience DailyGenerating mature and viable heart muscle cells from human or other animal stem cells has proven difficult for biologists. Now, Johns Hopkins rese… Continue reading

2017-01-26 Michael Zand NEWS

Scientists create mature heart muscle cells from stem cells – UPI.com

UPI.comScientists create mature heart muscle cells from stem cellsUPI.comJan. 26 (UPI) — Researchers at Johns Hopkins University School of Medicine have successfully generated mature heart muscle cells using stem cells. The mature heart muscle cells w… Continue reading

2017-01-26 Michael Zand NEWS

Platelets Can Deliver Immunotherapies Directly to Cancer Cells, Preventing Harm Elsewhere, Study Shows – Immuno-Oncology News

Cellecta Awarded Phase II SBIR Grant to Finalize Development of CRISPR Screening Platform
GenomeWeb
NEW YORK (GenomeWeb) – Cellecta announced today that it has been awarded a Phase II SBIR grant from the National Institutes of Health to complete development of a genome-wide CRISPR/Cas9 screening platform that it aims to commercialize by late …
Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA Library …Military Technologies

all 2 news articles »

Continue reading

2017-01-26 Michael Zand NEWS

Platelets Can Deliver Immunotherapies Directly to Cancer Cells, Preventing Harm Elsewhere, Study Shows – Immuno-Oncology News


Immuno-Oncology News

Platelets Can Deliver Immunotherapies Directly to Cancer Cells, Preventing Harm Elsewhere, Study Shows
Immuno-Oncology News
Immunotherapy has shown promise in eliminating the microtumors that sometimes remain after cancer surgery, but the treatment’s effects on other parts of the body have raised concern. Platelets could be the answer, researchers have discovered. The tiny …

and more »

Continue reading

2017-01-26 Michael Zand NEWS

Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA Library … – Yahoo Finance

Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA Library …Yahoo Finance26, 2017 /PRNewswire/ — Cellecta, Inc. today announced the receipt of Phase II SBIR grant funds from the National Institute of He… Continue reading

2017-01-26 Michael Zand NEWS

Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNA – PR Newswire (press release)

Cellecta, Inc. Receives Phase II NIH SBIR Grant to Develop Advanced CRISPR/Cas9 Genome-Wide sgRNAPR Newswire (press release)MOUNTAIN VIEW, Calif., Jan. 26, 2017 /PRNewswire/ — Cellecta, Inc. today announced the receipt of Phase II SBIR grant funds fro… Continue reading

2017-01-26 Michael Zand NEWS
  • 1
  • …
  • 2,174
  • 2,175
  • 2,176
  • 2,177
  • 2,178
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Immuno-Oncology News

Platelets Can Deliver Immunotherapies Directly to Cancer Cells, Preventing Harm Elsewhere, Study Shows
Immuno-Oncology News
Immunotherapy has shown promise in eliminating the microtumors that sometimes remain after cancer surgery, but the treatment’s effects on other parts of the body have raised concern. Platelets could be the answer, researchers have discovered. The tiny …

and more »